Alameda, United States
Alveo Technologies, established in 2015, is a pioneering venture in the Health Care and Medical Devices sectors, headquartered in the United States. The company’s mantra, "Know Sooner, Act Faster™," reflects its commitment to making molecular detection and diagnostics universally accessible.
Utilizing a patented technology, Alveo offers a portable diagnostic platform capable of direct electrical sensing of nucleic acid amplification. This innovation provides affordable, rapid, and accurate detection of pathogens at the Point of Need™, which is crucial for mitigating the spread of viruses, fungi, and bacteria.
Their solution addresses critical global challenges such as health management, food security, and supply chain resilience by delivering actionable insights swiftly. The company last received a Series A investment on 01 May 2021 from BDV Fund, highlighting investor confidence in their mission and technological prowess.
